METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS

• US 20140343118A1
• Filed: 03/14/2014
• Published: 11/20/2014
• Est. Priority Date: 03/14/2013
• Status: Abandoned Application

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: McCafferty, Dewey G., Pollock, Julie A., Gooden, David M., Hwang, Sunhee
• Application Number:
  US14/210,848
• Publication Number:
  US 20140343118A1
• Time in Patent Office: Days
• US Class Current: 514/438
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/145 having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) isothiourea A61K31/155
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 31/36 Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• CPC Class Codes: A61K 31/381 having five-membered rings
• CPC Class Codes: A61K 31/403 condensed with carbocyclic rings, e.g. carbazole
• CPC Class Codes: A61K 31/4453 only substituted in position 1, e.g. propipocaine, diperodon
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07D 317/58 Radicals substituted by nitrogen atoms nitro radicals C07D317/52
• CPC Class Codes: C07D 333/20 by nitrogen atoms nitro, nitroso radicals C07D333/12

Abstract

Described herein are methods of treating breast cancer using arylcyclopropylamine compounds.

Claims

1. A method of treating breast cancer in a subject in need of treatment, comprising administering to the subject an effective amount of a compound of formula (I):

2. The method of claim 1, wherein R₁, R₂, R₄ and R₅ are hydrogen.

3. The method of claim 1, wherein R₃ is selected from C_1-7 haloalkyl, halo, C_1-7 alkoxy, and C_5-20 aryloxy.

4. The method of claim 1, wherein R₂ and R₃ are taken together with the carbon atoms to which they are attached to form a C_3-20 heterocyclyl ring.

5. The method of claim 4, wherein R₂ and R₃ are taken together to form a five-membered heterocyclyl ring.

6. The method of claim 1, wherein R₆ is hydrogen.

7. The method of claim 1, wherein the compound of formula (I) is selected from the group consisting of:

36. The method of claim 1 wherein the breast cancer is estrogen-receptor negative.

73. The method of claim 1, wherein the compound is administered in combination with another breast cancer therapy.

74. The method of claim 73, wherein the cancer therapy is radiation.

75. The method of claim 73, wherein the cancer therapy is an anti-cancer agent.

76. The method of claim 73, wherein the cancer therapy is surgery.

8. A method of treating breast cancer in a subject in need of treatment, comprising administering to the subject an effective amount of a compound of formula (II):

9. The method of claim 8, wherein the compound is of formula (III):

10. The method of claim 8, wherein the compound is of formula (IV):

11. The method of claim 8, wherein the compound is of formula (V):

12. The method of claim 8, wherein the compound is of formula (VI):

17. The method of claim 8, wherein the compound is of formula (VII):

18. The method of claim 8, wherein the compound is of formula (VIII):

13-16. -16. (canceled)

19. A method of treating breast cancer in a subject in need of treatment, comprising administering to the subject an effective amount of a compound of formula (IX):

20. The method of claim 19, wherein A is a heterocyclyl ring.

21. The method of claim 19, wherein A is a bicyclic heterocyclyl ring.

22. The method of claim 19, wherein the compound is of formula (X):

23. The method of claim 19, wherein the compound is of formula (XI):

24. The method of claim 19, wherein the compound is of formula (XII):

25. The method of claim 19, wherein the compound is of formula (XIII):

26. The method of claim 19, wherein the compound is of formula (XIV):

27-28. -28. (canceled)

29. A method of treating breast cancer in a subject in need of treatment, comprising administering to the subject an effective amount of a compound of formula (XV):

30-35. -35. (canceled)

37. A method of reducing proliferation of breast cancer cells, comprising contacting the breast cancer cells with an effective amount of a compound of formula (I):

72. The method of claim 37 wherein the breast cancer cell is estrogen-receptor negative.

77. The method of claim 37, wherein the compound is administered in combination with another breast cancer therapy.

78. The method of claim 77, wherein the cancer therapy is radiation.

79. The method of claim 77, wherein the cancer therapy is an anti-cancer agent.

80. The method of claim 77, wherein the cancer therapy is surgery.

38-71. -71. (canceled)